Treatment Regimens of Neovascular Form of Age-Related Macular Degeneration. A Review

České info

Liečebné režimy neovaskulárnej formy vekom podmienenej makulárnej degenerácie. Prehľad

Článok podáva prehľad o liečebných režimoch liečiv s obsahom antivaskulárneho endotelového rastového faktora na liečbu neovaskulárnej formy vekom podmienenej makulárnej degenerácii. V súčasnosti sú liečivá s obsahom antivaskulárneho endotelového rastového faktora jedinou účinnou liečbou tohto chronického a progredujúceho ochorenia. Liečebné režimy tohto ochorenia v posledných dvoch desaťročiach zaznamenali posun od obyčajnej snahy o stabilizáciu choroby k dosiahnutiu maximálneho zlepšenia zrakovej ostrosti a jej udržanie so zlepšením kvality života pacienta a minimálnou liečebnou záťažou pacienta a jeho rodiny. Ďalšími cieľmi alternatívnych dávkovacích režimov, ktoré nahradili pôvodné fixné režimy boli väčšia individualizácia dávkovacieho režimu, lepšia spolupráca pacienta, šetrenie finančných nákladov a zníženie záťaže v aplikačných centrách. Vekom podmienená makulárna degenerácia, či jej suchá forma alebo vlhká forma predstavuje závažný zdravotný a socioekonomický problém, nakoľko ochorenie patrí medzi najčastejšiu príčinu závažnej a ireverzibilnej poruchy centrálnej zrakovej ostrosti až na úroveň praktickej slepoty jedného alebo obidvoch očí u ľudí nad 50 rokov vo vyspelých priemyselných krajinách. Najdôležitejšia je skorá diagnostika tohto ochorenia a následne promptná a kontinuálna liečba individualizovaným proaktívnym liečebným režimom s cieľom stabilizovať a zlepšiť anatomické a funkčné výsledky.

Klíčová slova:

režimy liečby – vaskulárne endotelové rastové faktory – antivaskulárne endotelové rastové faktory – neovaskulárna forma vekom podmienenej makulárnej degenerácie

Authors: Zlatica Fellner ^1,2; Nora Majtánová ^1,2; Petr Kolář ^1,2; Petra Krišková ¹; Petra Kéri ¹
Authors place of work: Očná klinika Slovenskej zdravotníckej univerzity a Univerzitnej nemocnice Bratislava ¹; Lekárska fakulta, Slovenská zdravotnícka univerzita, Bratislava ²
Published in the journal: Čes. a slov. Oftal., 80, 2024, No. Ahead of print, p. 1-7
Category: Přehledový článek
doi: https://doi.org/10.31348/2024/25

Summary

This article presents an overview of treatment regimens of drugs containing antivascular endothelial growth factor for the treatment of neovascular

form of age-related macular degeneration. Currently, drugs containing antivascular endothelial growth factor are the only effective treatment for this chronic and progressive disease. The treatment regimens for this disease in the last two decades have seen a shift from a simple endeavor to stabilize the disease to achieving maximum improvement of visual acuity and its maintenance, with improvement of the patient's quality of life and a minimal treatment burden on patients and their families. Other goals of the alternative dosing regimens that have replaced the original fixed regimens were greater individualization of the dosing regimen, better patient cooperation, saving financial costs and reducing the burden on application centers. Age-related macular degeneration, whether dry form or wet form, represents a serious health and socioeconomic problem, as the disease is one of the most common causes of severe and irreversible central visual acuity disorders up to the degree of practical blindness of one or both eyes in people over 50 years of age in developed industrialized countries. The most important issue is to ensure early diagnosis of this disease, followed by prompt and continuous treatment with an individualized proactive treatment regimen, with the aim of stabilizing and improving anatomical and functional results.

Keywords:

vascular endothelial growth factor – treatment regimens – antivascular endothelial growth factors – neovascular age-related macular degeneration

Stránka z

Zdroje

Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci.2023 Aug;24(16):13004. doi. org/10.3390/ijms241613004
Campa C, Costagliola C, Incorvaia C, et al. Inflammatory ediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010 Aug;2010. pii: 546826. doi. org/10.1155/2010/546826
Stěpanov A, Studnicka J. Použití anti-VEGF léku v oftalmologii. Klin Farmakol Farm. 2019;33(1):19-24. Czech. doi:10.36290/ far.2019.032
Heloterä H, Kaarniranta K. A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration. Cells. 2022;11(21):3453. doi.org/10.3390/cells11213453
Kaiser SM, Arepalli S, Ehlers JP. Current and future anti-VEGF agents for neovascular age-related macular degeneration. J Exp Pharmacol. 2021;13:905-912. doi:10.2147/JEP.S259298
Gualino V, Tadayoni R, Cohen SY, et al. Optical coherence tomography, fluorescein angiography, and diagnosis of choroidal neovascularization in age-related macular degeneration. Retina. 2019 Sep;39(9):1664-1671. doi:10.1097/IAE.0000000000002220
Told R, Sacu S, Hecht A, et al. Comparison of SD-Optical coherence tomography angiography and indocyanine green angiography in Type 1 and 2 Neovascular Age-related Macular Degeneration. IOVS. 2018 May;59(6):2393-2400. doi:10.1167/iovs.17-22902
Rocholz R, Corvi F, Weichsel J, Schmid S, Strarenghi G. High resolution imaging in microscopy and ophthalmology: New frontiers in biomedical optics [Internet]. Cham (Switzerland): Springer; 2019. Chapter 6, OCT Angiography (OCTA) in retinal diagnostics; p. 135-160. doi:10.1007/978-3-030-16638-0
Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021 Feb;9(1):62-79. doi:10.1016/j.gendis.2021.02.009
Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020 Jul;117(29-30):513-520. doi:10.3238/ arztebl.2020.0513
Hang A, Feldman S, Amin AP, et al. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals. 2023;16(8):1140. doi:10.3390/ph16081140
Luu KT, Seal J, Green M, Winskill C, Attar M. Effect of Anti‐VEGF therapy on the disease progression of neovascular age‐related macular degeneration: A systematic review and model‐based meta‐ analysis. J Clin Pharmacol. 2022 May;62(5):594-608. doi:10.1002/ jcph.2002
Song D, Liu P, Shang K, et al. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Fron Bioeng Biotechnol.2020;10:943915. doi:10.3389/fbioe.2022.943915
Hariprasad SM, Gale RP, Weng ChY, et al. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther. 2022;11:959-982. doi.:10.1007/s40123-02200488-w
Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25:815-827.
Plyukhova AA, Budzinskaya MV, Starostin KM, et al. Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): A systematic review and network meta-analysis of direct comparative studies. J.Clin.Med. 2020;9(5):1522. doi:10.3390/jcm9051522
DeCroos FCh, Reed D, Adam MK, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142-150. doi:10.1016/j.ajo.2017.06.002
Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963-976. doi:10.1016/j.ophtha.2019.12.031
Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345-1359. doi:10.1016/j.ophtha.2020.04.017
Khanani AM, Guymer RH, Basu, et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021 Nov;1(4):100076. doi:10.1016/j.xops.2021.100076
Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the treatment of neovascular age-Related macular degeneration and diabetic macular edema: A Review. Int J Mol Sci. 2022 Aug;23(16):9424. doi:10.3390/ijms23169424
Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. The efficacy, safety, and efficiency of the off-Label use of bevacizumab in patients diagnosed with age-related macular degeneration: Protocol for a systematic review and meta-analysis. JMIR Res Protoc.2023; 12: e38658. doi:10.2196/3858
Khanna S, Komati R, Eichenbaum DA, et al. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398. doi:10.1136/bmjophth-2019-000398
Horner F, Lip PL, Mohammed BR, et al. Comparing effectiveness of three different anti-VEGF treatment regimens for neovascular age-related macular degeneration: two years’ real-world clinical outcomes. Clin Ophthalmol. 2021 Apr;23(15):1703-1713. doi:10.2147/OPTH.S305141
Gemenetzi M, Patel PJ. A Systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-Related macular degeneration. Ophthalmol Ther. 2017;6:79-92. doi:10.1007/s40123-017-0087-5
Patel PJ, Villavicencio P, Hanumunthadu D. Systematic review of neovascular age-related macular degeneration disease activity criteria use to shorten, maintain or extend treatment intervals with anti-VEGF in clinical trials: implications for clinical practice. Ophthalmol Ther. 2023;12:2323-2346. doi:10.1007/s40123-02300768-z
Abdin AD, Mohamed A, Munteanu C, et al. Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration. Int J Retina Vitreous.2021;7:74. doi:10.1186/s40942-021-00349-x
Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2022 Apr;37(1):6-16. doi:10.1038/s41433-022-02020-7
https://health.gov.sk › Zdroje › Oftlamologia-Liecba-vlhkej-formy-vekom-podmienenej-degeneracie-makuly-anti-VEGF-liek mi-prostr-rezimu-Treat-and-Extend